NeuroPace (NASDAQ:NPCE) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

NeuroPace (NASDAQ:NPCE) released its quarterly earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07, Zacks reports. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%.

NeuroPace Price Performance

NPCE traded up $0.11 on Tuesday, reaching $11.92. The company had a trading volume of 245,578 shares, compared to its average volume of 119,388. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. NeuroPace has a 52-week low of $5.45 and a 52-week high of $16.34. The company has a market cap of $355.79 million, a price-to-earnings ratio of -11.92 and a beta of 2.05. The business has a 50 day simple moving average of $12.70 and a 200 day simple moving average of $9.71.

Insider Transactions at NeuroPace

In other NeuroPace news, insider Martha Morrell sold 3,200 shares of NeuroPace stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now directly owns 87,062 shares of the company’s stock, valued at approximately $1,306,800.62. This trade represents a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. Insiders have sold 5,352,479 shares of company stock valued at $50,670,217 in the last quarter. Insiders own 22.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on NPCE. Wells Fargo & Company lifted their target price on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, January 30th. UBS Group began coverage on shares of NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their price objective on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, NeuroPace currently has an average rating of “Moderate Buy” and a consensus target price of $14.80.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.